Manila Times Business
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI, June 5, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for inflammatory bowel disease (IBD). 9MW5211 is the first candidate drug for its target to enter clinical stage globally. 9MW5211 is a highly specific, depletin
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
Just now
From Mythical Prophecy to Realism: The Rational Turn of Hu Jiaqi's Doomsday Philosophy
Just now
Energy Awaits When Summer Comes to Play at Galaxy Macau
Just now
Trip.com Kicks Off Winter Travel Season with EOFY Mega Sale and Massive Flight Perks
Just now